Novel drug for osteoarthritic pain

• FDA approved in 2016 for Dogs
• Belongs to Piprant class of drugs
• Non-cyclooxygenase (COX)- inhibiting NSAID Prostaglandin Receptor Antagonists (PRA)

Benefits of Grapitail:

• First-in-Class-Non-COX Inhibiting NSAID- Grapiprant is a prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID that specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation
• Use for All Stages of OA- Grapiprant can be used for all stages of canine OA, from the earliest clinical signs, and can be used as long as needed
• Safe to use Daily- Grapiprant is safe to use daily to deliver effective canine OA pain management
• Targeted Pain Relief-Blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation
• Lower side effects-Reduces impact GI, Kidney and liver homeostasis

Indications:

• Grapitail (Grapiprant tablets) is indicated for the control of pain and inflammation associated with osteoarthritis in dogs

Dosage:

2 mg/kg once daily

It should be given empty stomach (e.g., in the morning) and at least

one hour before the next meal, once daily at a target dose of 2 mg per kg body weight

Presentation: Each box contains 10 blisters, and each blister contains 6 tablets

For dogs only